Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 922 of 3330
Next
>>
>
23026 to 23050 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.0213	uM	5896.091	0.9335	0.9102	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.107	uM	5896.091	0.7330	0.6257	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.533	uM	5896.091	0.5150	0.2846	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	2.67	uM	5896.091	0.4947	0.2504	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	13.3	uM	5896.091	0.4650	0.1998	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	66.7	uM	5896.091	0.4081	0.0999	1.4988
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.000171	uM	5897.091	0.9741	0.9577	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.000853	uM	5897.091	1.0193	1.0313	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.00427	uM	5897.091	1.0146	1.0237	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.0213	uM	5897.091	0.9809	0.9688	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.107	uM	5897.091	0.9768	0.9621	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	0.533	uM	5897.091	0.7470	0.5777	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	2.67	uM	5897.091	0.6579	0.4229	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	13.3	uM	5897.091	0.4764	0.0943	1.2296
184B5	NM	Basal	Erlotinib	EGFR	ErbB	66.7	uM	5897.091	0.4447	0.0348	1.2296
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.000171	uM	5898.091	1.0117	1.0380	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.000853	uM	5898.091	0.9467	0.8298	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.00427	uM	5898.091	0.9404	0.8101	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.0213	uM	5898.091	0.9549	0.8557	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.107	uM	5898.091	0.9551	0.8561	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.533	uM	5898.091	0.8748	0.6097	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	2.67	uM	5898.091	0.8616	0.5704	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	13.3	uM	5898.091	0.8116	0.4251	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	66.7	uM	5898.091	0.8510	0.5391	0.6159
600MPE	HR+	Luminal	Erlotinib	EGFR	ErbB	0.000171	uM	5899.09	0.9679	0.9382	1.0401

|<
<<
Previous
Page 922 of 3330
Next
>>
>
23026 to 23050 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)